Xenon Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Xenon Pharmaceuticals's earnings have been declining at an average annual rate of -35.8%, while the Biotechs industry saw earnings growing at 29.1% annually. Revenues have been declining at an average rate of 49.8% per year.
Key information
-35.79%
Earnings growth rate
-25.11%
EPS growth rate
| Biotechs Industry Growth | 17.04% |
| Revenue growth rate | -49.85% |
| Return on equity | -59.46% |
| Net Margin | -4,612.13% |
| Last Earnings Update | 31 Dec 2025 |
Recent past performance updates
Recent updates
Xenon's Phase 3 Supports A 'Buy' Despite Its Premium
Apr 22
Epilepsy And Depression Pipeline Will Define Fair Long Term Outlook
Catalysts About Xenon Pharmaceuticals Xenon Pharmaceuticals is a neuroscience focused biopharma company developing ion channel based therapies for epilepsy, depression, bipolar disorder and pain. What are the underlying business or industry changes driving this perspective?
Late Stage Neuroscience Pipeline Will Transform Ion Channel Franchise Over The Coming Years
Catalysts About Xenon Pharmaceuticals Xenon Pharmaceuticals is a neuroscience focused biopharma company developing ion channel targeted medicines for epilepsy, neuropsychiatric conditions and pain. What are the underlying business or industry changes driving this perspective?Xenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth Plans
Oct 01
We're Not Very Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Rate
May 07Xenon- A Later Stage Story
Apr 18Xenon Pharmaceuticals: 2025 Could Be Pivotal For Azetukalner's Epilepsy Potential
Jan 16Xenon Pharmaceuticals: Good Data In Epilepsy, But Doubts Remain
Aug 09Xenon Pharmaceuticals: Analysts Still Positive Despite Recent Trial 'Setbacks'
Feb 08Xenon started at outperform at Raymond James on experimental epilepsy drug
Oct 19Putting Xenon Pharmaceuticals Back In The Spotlight
Sep 06Xenon initiated with Buy at BofA citing potential of anti-seizure drug
Aug 29Sizing Up Xenon Pharmaceuticals
Dec 13Revenue & Expenses Breakdown
How Xenon Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 25 | 8 | -346 | 80 | 0 |
| 30 Sep 25 | 8 | -306 | 76 | 0 |
| 30 Jun 25 | 8 | -278 | 73 | 0 |
| 31 Mar 25 | 8 | -251 | 73 | 0 |
| 31 Dec 24 | 0 | -234 | 69 | 0 |
| 30 Sep 24 | 0 | -213 | 64 | 0 |
| 30 Jun 24 | 0 | -199 | 60 | 0 |
| 31 Mar 24 | 0 | -189 | 52 | 0 |
| 31 Dec 23 | 0 | -182 | 47 | 0 |
| 30 Sep 23 | 0 | -175 | 42 | 0 |
| 30 Jun 23 | 0 | -164 | 38 | 0 |
| 31 Mar 23 | 1 | -147 | 36 | 0 |
| 31 Dec 22 | 9 | -125 | 33 | 0 |
| 30 Sep 22 | 13 | -113 | 31 | 0 |
| 30 Jun 22 | 21 | -91 | 27 | 0 |
| 31 Mar 22 | 23 | -83 | 25 | 0 |
| 31 Dec 21 | 18 | -77 | 22 | 0 |
| 30 Sep 21 | 20 | -66 | 18 | 0 |
| 30 Jun 21 | 18 | -59 | 17 | 0 |
| 31 Mar 21 | 29 | -37 | 14 | 0 |
| 31 Dec 20 | 32 | -29 | 13 | 0 |
| 30 Sep 20 | 30 | -28 | 13 | 0 |
| 30 Jun 20 | 27 | -28 | 13 | 0 |
| 31 Mar 20 | 14 | -38 | 12 | 0 |
| 31 Dec 19 | 7 | -42 | 11 | 0 |
| 30 Sep 19 | 4 | -39 | 10 | 0 |
| 30 Jun 19 | 0 | -44 | 9 | 0 |
| 31 Mar 19 | 0 | -42 | 9 | 0 |
| 31 Dec 18 | 0 | -34 | 8 | 0 |
| 30 Sep 18 | 0 | -34 | 8 | 0 |
| 30 Jun 18 | 0 | -27 | 8 | 0 |
| 31 Mar 18 | 0 | -27 | 7 | 0 |
| 31 Dec 17 | 0 | -31 | 7 | 0 |
| 30 Sep 17 | 1 | -29 | 7 | 4 |
| 30 Jun 17 | 1 | -29 | 7 | 10 |
| 31 Mar 17 | 1 | -27 | 7 | 15 |
| 31 Dec 16 | 2 | -23 | 7 | 19 |
| 30 Sep 16 | 5 | -21 | 7 | 18 |
| 30 Jun 16 | 9 | -17 | 6 | 16 |
| 31 Mar 16 | 12 | -10 | 5 | 14 |
| 31 Dec 15 | 16 | -16 | 10 | 12 |
| 30 Sep 15 | 17 | -2 | 10 | 11 |
| 30 Jun 15 | 26 | 5 | 10 | 9 |
Quality Earnings: XENE is currently unprofitable.
Growing Profit Margin: XENE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: XENE is unprofitable, and losses have increased over the past 5 years at a rate of 35.8% per year.
Accelerating Growth: Unable to compare XENE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: XENE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (50.1%).
Return on Equity
High ROE: XENE has a negative Return on Equity (-59.46%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/28 23:15 |
| End of Day Share Price | 2026/04/28 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Xenon Pharmaceuticals Inc. is covered by 25 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Jason Matthew Gerberry | BofA Global Research |
| John Newman | Canaccord Genuity |